Please login to the form below
Torii
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Torii's Japan sales performance.
Myovant preps US filing for relugolix in prostate cancer
of 2020 and in Europe and Japan a little later, says the biotech.
FDA advisors say no to empagliflozin in type 1 diabetes
Europe as well as Japan.
Pharmaceutical innovation in the APAC region
We examined these factors for Mainland China, Japan and South Korea, concluding, very broadly:. ... Cancer will remain a growth market, although Japan is currently experiencing price containment pressures that other countries will also ultimately face.
Sandoz expands into Japan with €400m Aspen deal
The acquisition will include shares in Aspen Japan K.K. and all associated assets held by AGI. ... Japan’s generic medicines market is the third largest globally, a fact which will aid Sandoz’ continuing growth – in Novartis’ recent third
Daiichi files lawsuit with Seattle over ADCs, including AZ-partnered DS-8201
Dispute covers multiple drugs in Daiichi's antibody-drug conjugates pipeline. A partnership between Seattle Genetics and Japan’s Daiichi Sankyo on antibody-drug conjugates, which ended in 2015, has sparked
[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- Regeneron says antibody for COVID-19 could be ready this year
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Amgen adds Otezla to the COVID-19 candidate list
- Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
- New data backs remdesivir for COVID-19, but rings hydroxychloroquine alarm bell
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Merrill Brink International
Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
